» Articles » PMID: 30662351

Remodeling the Microenvironment Before Occurrence and Metastasis of Cancer

Overview
Journal Int J Biol Sci
Specialty Biology
Date 2019 Jan 22
PMID 30662351
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Tumorigenesis and progression of cancer are complex processes which transformed cells and stromal cells interact and co-evolve. Intrinsic and extrinsic factors cause the mutations of cells. The survival of transformed cells critically depends on the circumstances which they reside. The malignant transformed cancer cells reprogram the microenvironment locally and systemically. The formation of premetastatic niche in the secondary organs facilitates cancer cells survival in the distant organs. This review outlines the current understanding of the key roles of premalignant niche and premetastatic niche in cancer progression. We proposed that a niche facilitates survival of transformed cells is characteristics of senescence, stromal fibrosis and obese microenvironment. We also proposed the formation of premetastatic niche in secondary organs is critically influenced by primary cancer cells. Therefore, it suggested that strategies to target the niche can be promising approach to eradicate cancer cells.

Citing Articles

Profiling the cancer-prone microenvironment in a zebrafish model for MPNST.

Cero C, House J, Verdi V, Ferguson J, Jima D, Selmek A Oncogene. 2024; 44(3):179-191.

PMID: 39511408 PMC: 11725499. DOI: 10.1038/s41388-024-03210-1.


Breast cancer therapy: from the perspective of glucose metabolism and glycosylation.

Zhao J, Sun H, Wang C, Shang D Mol Biol Rep. 2024; 51(1):546.

PMID: 38642246 DOI: 10.1007/s11033-024-09466-w.


Premetastatic Niche: A Novel Area for Research in Metastasis with a Potential as Therapeutic Targeting in Oral Cancer.

Geetha R, Janardhanan M, Thankappan K, Iyer S J Pharm Bioallied Sci. 2023; 15(Suppl 1):S36-S39.

PMID: 37654347 PMC: 10466595. DOI: 10.4103/jpbs.jpbs_49_23.


Immune determinants of the pre-metastatic niche.

Patras L, Shaashua L, Matei I, Lyden D Cancer Cell. 2023; 41(3):546-572.

PMID: 36917952 PMC: 10170403. DOI: 10.1016/j.ccell.2023.02.018.


Targeting tumor exosomal circular RNA cSERPINE2 suppresses breast cancer progression by modulating MALT1-NF-????B-IL-6 axis of tumor-associated macrophages.

Zhou B, Mo Z, Lai G, Chen X, Li R, Wu R J Exp Clin Cancer Res. 2023; 42(1):48.

PMID: 36797769 PMC: 9936722. DOI: 10.1186/s13046-023-02620-5.


References
1.
Guo Y, Nemeth J, OBrien C, Susa M, Liu X, Zhang Z . Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Clin Cancer Res. 2010; 16(23):5759-69. DOI: 10.1158/1078-0432.CCR-10-1095. View

2.
Blagosklonny M . Cell cycle arrest is not senescence. Aging (Albany NY). 2011; 3(2):94-101. PMC: 3082019. DOI: 10.18632/aging.100281. View

3.
Parker M, Rossi D, Peterson M, Smith K, Sikstrom K, White E . Fibrotic extracellular matrix activates a profibrotic positive feedback loop. J Clin Invest. 2014; 124(4):1622-35. PMC: 3971953. DOI: 10.1172/JCI71386. View

4.
Maggio M, Guralnik J, Longo D, Ferrucci L . Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci. 2006; 61(6):575-84. PMC: 2645627. DOI: 10.1093/gerona/61.6.575. View

5.
Sun Q, Liu Q, Zheng Y, Cao X . Rapamycin suppresses TLR4-triggered IL-6 and PGE(2) production of colon cancer cells by inhibiting TLR4 expression and NF-kappaB activation. Mol Immunol. 2008; 45(10):2929-36. DOI: 10.1016/j.molimm.2008.01.025. View